BD Improving Global Health

1
BDImproving Global Health
Leveraging Corporate Core Competencies to TB and
HIV23 March 2009Stop TB Partners ForumRio De
Janeiro
Krista Thompson Vice President and General
Manager Global Health BD (Becton Dickinson and
Company)
2
BD Who We Are

• Leading global medical technology company
• Focused on
• Enhancing quality and speed of diagnosing
  infectious diseases
• Improving drug therapy
• Advancing research and discovery of new drugs and
  vaccines
• Capabilities instrumental in combating many of
  the worlds most pressing diseases
• Dedicated to improving peoples health throughout
  the world

3
Healthcare Systems Strengthening

• The ability to address crises like the HIV and TB
  pandemics is being hampered by fundamentally weak
  healthcare systems
• While more funding is always critical, money
  alone cannot solve the healthcare problems of the
  developing world
• Building sustainable healthcare systems will
  benefit everyone from the patients, to the
  healthcare professionals to the governments of
  these developing world nations

4
BDs Unique Approach
Increasing access to critical technologies Provid
ing technical assistance Investing in new
technologies Supporting volunteerism and
philanthropy
Collaboration with leading public private
organizations
5
Increasing Access to Critical Technologies
6
Increasing Access to Critical Technologies

• Immune System Monitoring
• existing technology, flow cytometry
• adapted for small clinics, BD FACSCount
• 10 years in advance of access to ARVs

• Clinton Foundation Agreement
• expanded accessibility of advanced CD4 cell
  counting technology systems
• offered deeply discounted pricing 75 percent
  less
• more than 3000 systems have been placed
• support agreement with training and service

7
Increasing Access to Critical Technologies

• TB Diagnosis Liquid Culture Technology
• existing technology, BD BACTEC MGIT 960 System
• liquid culture shortens time to diagnosis from 4
  to 6 weeks to 10 to 14 days

• Foundation for Innovative New Diagnostics (FIND)
• collaborating to improve diagnosis of TB
• established demonstration sites in Africa,
  Eastern Europe, Russia, and Asia
• WHO new guidelines for increased use of liquid
  culture
• pricing agreement for BD BACTEC MGIT 960 System

8
Providing Technical Assistance
9
Providing Technical Assistance

• Good Laboratory Practice Training
• collaborations with local governments, NGOs and
  philanthropic partners worldwide to train
  laboratory workers to improve laboratory
  procedures
• implemented in 58 countries and nearly 5,000
  participants trained in more than 500 workshops
• collaborated with Stellenbosch University in
  South Africa and the Kenyan Medical Research
  Institute (KEMRI) in Kenya to open training
  centers for CD4 applications and basic lab
  procedures
• BD Volunteer Program
• In 2005 and 2006, collaborated with the Catholic
  Medical
• Mission Board to send BD Associates to HIV/AIDS
  clinics in Zambia
• In 2007 and 2008, collaborating with Direct
  Relief International to send BD associates to
  healthcare facilities in Ghana

10
Providing Technical Assistance

• BD/PEPFAR Lab Strengthening Collaboration
• Unprecedented 18 million, five-year
  collaboration with Presidents Emergency Plan for
  AIDS Relief
• Focus is strengthening lab practices and systems
• Majority of BD commitment is in-kind services
  (lab practices training, strengthening of TB
  reference sites)
• Compelling example of how global company and US
  government can join forces to benefit developing
  world

11
Investing in New Technologies
12
Investing in New Technologies

• Immunization
• BD SoloShot
• BD Uniject
• Curative
• BD SoloMed
• BD SoloMed with SafetyShield
• Sharps Disposal
• BD HubCutter
• Collaboration with WHO and other international
  agencies

13
Investing in New Technologies

• BD Vacutainer CD4 Stabilization Blood
  Collection Tube in Africa
• stabilizes CD4 cells for longer time and at
  higher temperatures
• enables samples to be taken in remote areas and
  transported to the labs for testing
• New BD FACSCount Reagent
• provides a CD4
• determination of percentages and absolute counts
  of human CD4 lymphocytes in whole blood
• reagent and accompanying software designed to be
  compatible with current FACSCount instrument
• currently in development

14
Investing in New Technologies

• Development of TB Core Team
• focused on identifying new TB diagnostic
  technologies
• Future Investments
• diagnostics for non-urban settings
• wider array of infectious diseases

15
Philanthropic Support
16
Partners
17

• There are no simple solutions to the complex
  challenges involved in delivering healthcare to
  patients in the developing world.
• BD is committed to deploying a wide range of
  resources aimed at making a lasting impact on
  these crises.
• Ongoing collaboration between public and private
  organizations is the only way that sustainable
  improvements will be made.

18
BD MGIT 960 Systems in High Burden Countries
China 55
gt900 MGIT 960 placements in Emerging Markets
Updated Sept07
14